Cargando…

Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression

BACKGROUND: Rilotumumab, an investigational, monoclonal antibody, inhibits MET-mediated signalling. In a randomized phase 2 trial of rilotumumab±epirubicin/cisplatin/capecitabine in gastric or oesophagogastric junction cancer, patients receiving rilotumumab showed a trend towards improved survival,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, M, Tang, R, Doshi, S, Oliner, K S, Dubey, S, Jiang, Y, Donehower, R C, Iveson, T, Loh, E Y, Zhang, Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453660/ https://www.ncbi.nlm.nih.gov/pubmed/25584489 http://dx.doi.org/10.1038/bjc.2014.649

Ejemplares similares

Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling
por: Cecchi, Fabiola, et al.
Publicado: (2023)

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
por: Affronti, Mary Lou, et al.
Publicado: (2018)

Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer
por: Karthaus, Meinolf, et al.
Publicado: (2016)

Are ipsilateral breast tumour invasive recurrences in young (⩽40 years) women more aggressive than their primary tumours?
por: Sigal-Zafrani, B, et al.
Publicado: (2007)

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours
por: Wilky, B A, et al.
Publicado: (2015)

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
por: Ahn, H K, et al.
Publicado: (2013)

Circulating tumour cells detected by a novel adenovirus-mediated system may be a potent therapeutic marker in gynaecological cancers
por: Takakura, M, et al.
Publicado: (2012)

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study
por: Valle, J W, et al.
Publicado: (2009)

Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study
por: Zhang, D S, et al.
Publicado: (2015)

Individually tailored screening of breast cancer with genes, tumour phenotypes, clinical attributes, and conventional risk factors
por: Wu, Y-Y, et al.
Publicado: (2013)

Prospective validation of quantitative CEA mRNA detection in peritoneal washes in gastric carcinoma patients
por: Ito, S, et al.
Publicado: (2005)

Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer
por: Takayama, T, et al.
Publicado: (2007)

Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma
por: Yamanaka, T, et al.
Publicado: (2007)

Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer
por: Yamaguchi, K, et al.
Publicado: (2006)

A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
por: Kang, Y-K, et al.
Publicado: (2014)

Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer
por: Li, Yilin, et al.
Publicado: (2016)

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
por: Kang, Y-K, et al.
Publicado: (2013)

S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study
por: Wang, X, et al.
Publicado: (2018)

Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours
por: Price, T J, et al.
Publicado: (2008)

The effects of preoperative chemotherapy on isolated tumour cells in the blood and bone marrow of gastric cancer patients
por: Kolodziejczyk, P, et al.
Publicado: (2007)

An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer
por: Chao, Y, et al.
Publicado: (2006)

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer
por: Han, S-W, et al.
Publicado: (2009)

A single institutional experience of thymic epithelial tumours over 11 years: clinical features and outcome and implications for future management
por: Lee, H-S, et al.
Publicado: (2007)

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
por: Martin, L P, et al.
Publicado: (2012)

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours
por: Doi, T, et al.
Publicado: (2012)

A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer
por: Park, Y H, et al.
Publicado: (2006)

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients
por: Koivunen, J P, et al.
Publicado: (2008)

Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group
por: Kim, J G, et al.
Publicado: (2008)

CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer
por: Yamamoto, N, et al.
Publicado: (2013)

Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours
por: Pan, Y, et al.
Publicado: (2011)

Incidence and prognostic value of tumour cells detected by RT–PCR in peripheral blood stem cell collections from patients with Ewing tumour
por: Vermeulen, J, et al.
Publicado: (2006)

Clinical outcome and risk factors for recurrence in borderline ovarian tumours
por: Yokoyama, Y, et al.
Publicado: (2006)

Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer
por: Baek, J H, et al.
Publicado: (2006)

Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)
por: Kurokawa, Y, et al.
Publicado: (2014)

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
por: Lee, J-L, et al.
Publicado: (2008)

Refining the role of laparoscopy and laparoscopic ultrasound in the staging of presumed pancreatic head and ampullary tumours
por: Thomson, B N J, et al.
Publicado: (2006)

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
por: Adenis, A, et al.
Publicado: (2013)

A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer
por: Oh, S C, et al.
Publicado: (2007)

A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours
por: Plummer, R, et al.
Publicado: (2011)

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
por: Yoon, D H, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_095ltd94nre5ccndlcip00g7dh